11 completed, 4 recruiting, 4 terminated, 1 unknown. 7 Phase 2, 4 Phase 3, 2 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Recruiting 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Not applicable | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Palmoplantar Pustulosis: new trials by email Literature Review of Palmoplantar Pustulosis trials Research Report on Palmoplantar Pustulosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Picankibart in Palmoplantar Pustulosis Picankibart - Palmoplantar Pustulosis | Not applicable | Recruiting | Xijing Hospital | 60 | 2026-04-15 | 2026-04-27 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis Bimekizumab, Placebo - Palmoplantar Pustulosis | Phase 3 | Recruiting | UCB Biopharma SRL | 320 | 2025-11-14 | 2026-08-27 |
| A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis Delgocitinib cream, Vehicle cream - Palmoplantar Pustulosis | Phase 2 | Recruiting | LEO Pharma | 135 | 2025-09-11 | 2026-10-01 |
| Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis Deucravacitinib - Palmoplantar Pustulosis | Not applicable | Terminated | Peking University First Hospital | 3 | 2025-06-20 | 2026-03-11 |
| Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists AI-based medical device for aided diagnosis in Dermatology - Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP) | Completed | AI Labs Group S.L | 15 | 2024-06-01 | 2026-02-24 | |
| Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers Blood samples collection, Oral samples collection, Hair samples collection - Acne, Atopic Dermatitis | Recruiting | Innovaderm Research Inc. | 500 | 2023-10-17 | 2026-03-30 | |
| Deucravacitinib for the Treatment of Palmoplantar Pustulosis Deucravacitinib - Palmoplantar Pustulosis | Phase 4 | Terminated | Brigham and Women's Hospital | 3 | 2023-07-01 | 2026-04-07 |
| Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) Apremilast, Placebo - Palmoplantar Pustulosis | Phase 3 | Completed | Amgen | 176 | 2022-03-08 | 2025-04-09 |
| A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) RIST4721, Placebo - Palmoplantar Pustulosis | Phase 2 | Terminated | Aristea Therapeutics, Inc. | 79 | 2022-01-05 | 2023-06-29 |
| A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan No intervention - Palmoplantar Pustulosis | Completed | Janssen Pharmaceutical K.K. | 276 | 2021-03-22 | 2026-02-10 | |
| A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab Spesolimab - Palmoplantar Pustulosis | Phase 2 | Terminated | Boehringer Ingelheim | 108 | 2020-09-04 | 2025-10-20 |
| A Study of KHK4827 in Subjects With Palmoplantar Pustulosis KHK4827, Placebo - Palmoplantar Pustulosis | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 126 | 2019-08-10 | 2023-02-14 |
| Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody - Hidradenitis Suppurativa, Palmoplantar Pustulosis | Phase 1 | Completed | CSL Behring | 39 | 2019-07-04 | 2023-05-26 |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis Imsidolimab, Placebo - Palmoplantar Pustulosis | Phase 2 | Completed | Vanda Pharmaceuticals | 59 | 2019-05-20 | 2025-09-15 |
| A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) RIST4721, Placebo - Palmoplantar Pustulosis | Phase 2 | Completed | Aristea Therapeutics, Inc. | 35 | 2019-02-13 | 2022-04-05 |
| Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) Apremilast - Palmoplantar Pustulosis | Phase 2 | Completed | Kristian Reich | 21 | 2018-11-29 | 2021-09-24 |
| An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis Guselkumab, Placebo - Palmoplantar Pustulosis | Phase 3 | Completed | Janssen Pharmaceutical K.K. | 159 | 2015-12-15 | 2025-02-04 |
| Anakinra for Inflammatory Pustular Skin Diseases Anakinra - Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau | Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 18 | 2013-07-22 | 2021-04-30 |
| Immune Signature of Palmoplantar Pustulosis Palmoplantar Pustulosis | Completed | Baylor Research Institute | 30 | 2013-06-01 | 2014-07-10 | |
| Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence prevalence/incidence - Palmoplantar Pustulosis, Generalized Pustular Psoriasis | Unknown | Peking University Third Hospital | 200 | 2012-01-01 | 2020-09-28 |
Psoriasis (20) · Hidradenitis Suppurativa (3) · Acne Vulgaris (2) · Acne Conglobata (1) · Acute Generalized Exanthematous Pustulosis (1) · Aggressive Periodontitis (1) · Dermatitis, Atopic (1) · Dermatitis, Seborrheic (1) · Impetigo (1) · Keratosis, Seborrheic (1) · Pemphigus (1) · Rare Diseases (1) · Skin Diseases (1) · Skin Diseases, Vesiculobullous (1) · Tinea (1)
Skin Diseases, Papulosquamous (20) · Skin and Connective Tissue Diseases (20) · Skin Diseases (19) · Bacterial Infections (3) · Bacterial Infections and Mycoses (3) · Hidradenitis (3) · Infections (3) · Skin Diseases, Bacterial (3) · Skin Diseases, Infectious (3) · Suppuration (3) · Sweat Gland Diseases (3) · Acneiform Eruptions (2) · Dermatitis (2) · Hypersensitivity (2) · Immune System Diseases (2)
apremilast (2) · deucravacitinib (2) · Granulocyte Colony-Stimulating Factor (1) · Incidence (1) · Interleukin 1 Receptor Antagonist Protein (1) · Prevalence (1) · bimekizumab (1) · brodalumab (1) · guselkumab (1) · spesolimab (1)
Aristea Therapeutics, Inc. (2) · Janssen Pharmaceutical K.K. (2) · AI Labs Group S.L (1) · Amgen (1) · Baylor Research Institute (1) · Boehringer Ingelheim (1) · Brigham and Women's Hospital (1) · CSL Behring (1) · Innovaderm Research Inc. (1) · Kristian Reich (1) · Kyowa Kirin Co., Ltd. (1) · LEO Pharma (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Peking University First Hospital (1) · Peking University Third Hospital (1)
Germany (8) · United States (8) · Canada (7) · Japan (5) · Poland (5) · United Kingdom (4) · China (3) · Czechia (3) · Hungary (3) · Australia (2) · Denmark (2) · France (2) · South Korea (2) · Spain (2) · Belgium (1)
Alan Menter, MD (1) · Antonio Martorell, PhD (1) · Edward W Cowen, M.D. (1) · Kristian Reich, MD, PhD (1) · Robert Bissonnette, MD (1) · Siyan Zhan, PhD (1)
PMID 31268476, PMID 34077577, PMID 34716902, PMID 38954226, PMID 41297955, PMID 42543660
2016 (1), 2017 (1), 2018 (1)